Effect of PPAR-γ agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus

Physiological Research

Volumn 56, Issue 6, 2007, Pages 741-748

  Dolezalova R ^a   Haluzik M M ^a,b   Bosanska L ^a   Lacinova Z ^a   Kasalova Z ^a   Stulc T ^a   Haluzik M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF OSTRAVA   (Czech Republic)

Author keywords

Adipocyte derived hormones; Cardiovascular risk; Diabetes mellitus; Endothelial dysfunction; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; LIPID; PEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; ROSIGLITAZONE; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOSE TISSUE; ARTICLE; BLOOD; BODY MASS; DIABETIC ANGIOPATHY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; VASCULAR ENDOTHELIUM;

ADIPOSE TISSUE; BIOLOGICAL MARKERS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERCELLULAR ADHESION MOLECULE-1; LIPIDS; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PEROXIDASE; PPAR GAMMA; RESISTIN; THIAZOLIDINEDIONES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 41749093666     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. ANDERLOVÁ K, KŘEMEN J, DOLEŽALOVÁ R, HOUSOVÁ J, HALUZÍKOVÁ D, KUNEŠOVÁ M, HALUZÍK M: The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese women. Physiol Res, 55: 277-283, 2006.
2. BERG AH, COMBS TP, SCHERER PE: ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13: 84-89, 2002.
3. BLASCHKE F, SPANHEIMER R, KHAN M, LAW RE: Vascular effects of TZDs: new implications. Vascul Pharmacol 45: 3-18, 2006.
4. BURAS J, REENSTRA WR, ORLOW D, HORTON ES, VEVES A: Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes. Obes Res 13: 1167-1174, 2005.
5. CABALLERO AE, SAOUAF R, LIM SC, HAMDY O, ABOU-ELENIN K, O'CONNOR C, LOGERFO FW, HORTON ES, VEVES A: The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 52: 173-180, 2003.
6. CERIELLO A: Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54: 1-7, 2005.
7. COMBS TP, WAGNER JA, BERGER J, DOEBBER T, WANG WJ, ZHANG BB, TANEN M, BERG AH, O'RAHILLY S, SAVAGE DB, CHATTERJEE K, WEISS S, LARSON PJ, GOTTESDIENER KM, GERTZ BJ, CHARRON MJ, SCHERER PE, MOLLER DE: Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143: 998-1007, 2002.
8. DANDONA P, ALJADA A, MOHANTY P, GHANIM H, BANDYOPADHYAY A, CHAUDHURI A: Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care 26: 3310-3314, 2003.
9. ESPER RJ, NORDABY RA, VILARINO JO, PARAGANO A, CACHARRON JL, MACHADO RA: Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 5: 4, 2006.
10. ESPOSITO K, CIOTOLA M, CARLEO D, SCHISANO B, SACCOMANNO F, SASSO FC, COZZOLINO D, ASSALONI R, MERANTE D, CERIELLO A, GIUGLIANO D: Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29: 1071-1076, 2006.
11. FRUCHART JC, GOTTO AM, PAOLETTI R, STAELS B, CATAPANO AL: PPARs: From Basic Science to Clinical Applications, 2002. Kluwer Academic Publishers, New York, Rome, 2002.
12. HAFFNER SM: Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 92: 18J-26J, 2003a.
13. HAFFNER SM: Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract 61 (Suppl 1): S9-S18, 2003b.
14. HAFFNER SM, LEHTO S, RONNEMAA T, PYORALA K, LAAKSO M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234, 1998.
15. HALUZÍK M, HALUZÍKOVÁ D: The role of resistin in obesity-induced insulin resistance. Curr Opin Investig Drugs 7: 306-311, 2006.
16. HALUZÍK MM, HALUZÍK M: PPAR-alpha and insulin sensitivity. Physiol Res 55: 115-122, 2006.
17. HALUZÍK M, PAŘÍZKOVÁ J, HALUZÍK MM: Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 53: 123-129, 2004.
18. HAVEL PJ: Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13: 51-59, 2002.
19. HOWARD G, O'LEARY DH, ZACCARO D, HAFFNER S, REWERS M, HAMMAN R, SELBY JV, SAAD MF, SAVAGE P, BERGMAN R: Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 93: 1809-1817, 1996.
20. HUO Y, LEY K: Adhesion molecules and atherogenesis. Acta Physiol Scand 173: 35-43, 2001.
21. KAWANAMI D, MAEMURA K, TAKEDA N, HARADA T, NOJIRI T, IMAI Y, MANABE I, UTSUNOMIYA K, NAGAI R: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314: 415-419, 2004.
22. KOMERS R, VRÁNA A: Thiazolidinediones - tools for the research of metabolic syndrome X. Physiol Res 47: 215-225, 1998.
23. KUBOTA N, TERAUCHI Y, YAMAUCHI T, KUBOTA T, MOROI M, MATSUI J, ETO K, YAMASHITA T, KAMON J, SATOH H, YANO W, FROGUEL P, NAGAI R, KIMURA S, KADOWAKI T, NODA T: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277: 25863-25866, 2002.
24. LEHMANN JM, MOORE LB, SMITH-OLIVER TA, WILKISON WO, WILLSON TM, KLIEWER SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270: 12953-12956, 1995.
25. LEHRKE M, REILLY MP, MILLINGTON SC, IQBAL N, RADER DJ, LAZAR MA: An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1: e45, 2004.
26. LIM HS, MACFADYEN RJ, BAKRIS G, LIP GY: The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management. Curr Pharm Des 12: 1567-1579, 2006.
27. LOVISCACH M, REHMAN N, CARTER L, MUDALIAR S, MOHADEEN P, CIARALDI TP, VEERKAMP JH, HENRY RR: Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia 43: 304-311, 2000.
28. MAYERSON AB, HUNDAL RS, DUFOUR S, LEBON V, BEFROY D, CLINE GW, ENOCKSSON S, INZUCCHI SE, SHULMAN GI, PETERSEN KF: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51: 797-802, 2002.
29. MCTERNAN CL, MCTERNAN PG, HARTE AL, LEVICK PL, BARNETT AH, KUMAR S: Resistin, central obesity, and type 2 diabetes. Lancet 359: 46-47, 2002.
30. MOORE KJ, ROSEN ED, FITZGERALD ML, RANDOW F, ANDERSSON LP, ALTSHULER D, MILSTONE DS, MORTENSEN RM, SPIEGELMAN BM, FREEMAN MW: The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7: 41-47, 2001.
31. NOLAN JJ, LUDVIK B, BEERDSEN P, JOYCE M, OLEFSKY J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188-1193, 1994.
32. OLEFSKY JM: Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106: 467-472, 2000.
33. PISCHON T, BAMBERGER CM, KRATZSCH J, ZYRIAX BC, ALGENSTAEDT P, BOEING H, WINDLER E: Association of plasma resistin levels with coronary heart disease in women. Obes Res 13: 1764-1771, 2005.
34. PLOMGAARD P, KELLER P, KELLER C, PEDERSEN BK: TNF-alpha, but not IL-6, stimulates plasminogen activator inhibitor-1 expression in human subcutaneous adipose tissue. J Appl Physiol 98: 2019-2023, 2005.
35. RAVUSSIN E, SMITH SR: Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 967: 363-378, 2002.
36. REAVEN GM: Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
37. REAVEN GM: Syndrome X. Blood Press Suppl 4: 13-16, 1992.
38. REAVEN G: Syndrome X. Curr Treat Options Cardiovasc Med 3: 323-332, 2001.
39. SALTIEL AR, OLEFSKY JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669, 1996.
40. SAVAGE DB, SEWTER CP, KLENK ES, SEGAL DG, VIDAL-PUIG A, CONSIDINE RV, O'RAHILLY S: Resistin/ Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50: 2199-2202, 2001.
41. SHIMADA K, MIYAZAKI T, DAIDA H: Adiponectin and atherosclerotic disease. Clin Chim Acta 344: 1-12, 2004.
42. STEPPAN CM, BAILEY ST, BHAT S, BROWN EJ, BANERJEE RR, WRIGHT CM, PATEL HR, AHIMA RS, LAZAR MA: The hormone resistin links obesity to diabetes. Nature 409: 307-312, 2001.
43. SU CG, WEN X, BAILEY ST, JIANG W, RANGWALA SM, KEILBAUGH SA, FLANIGAN A, MURTHY S, LAZAR MA, WU GD: A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104: 383-389, 1999.
44. TAN GD, FIELDING BA, CURRIE JM, HUMPHREYS SM, DESAGE M, FRAYN KN, LAVILLE M, VIDAL H, KARPE F: The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48: 83-95, 2005.
45. TSIOUFIS C, DIMITRIADIS K, CHATZIS D, VASILIADOU C, TOUSOULIS D, PAPADEMETRIOU V, TOUTOUZAS P, STEFANADIS C, KALLIKAZAROS I: Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 96: 946-951, 2005.
46. VAMECQ J, LATRUFFE N: Medical significance of peroxisome proliferator-activated receptors. Lancet 354: 141-148, 1999.